Introduction/Background To evaluate the platelet counts as a prognostic parameter for ovarian tumours.
Methodology Between 2000 and 2005, 349 patients with ovarian tumours (aged 12–88-years-old) underwent primary surgical treatment at First Department of Obstetrics and Gynecology. 97 patients were diagnosed with ovarian malignancies and borderline tumours: adenocarcinoma (64,9%), carcinoma endometrioides (13,4%), carcinoma clarocellulare (10,3%), carcinoma endometrioides and adenocarcinoma serosus(1,0%) cystadenocarcinoma papillarae of borderline malignancy (5,1%), cystadenofibroma papillarae of borderline malignancy (2,0%) cystadenoma mucinosum of borderline malignancy (1,0%), Sertoli Leyding tumour (2,0%).
Thrombocytopaenia was assumed with a platelet count below 150G/L and thrombocythaemia at 350G/L and higher. The patients were retrospectively evaluated and compared.
Results Thrombocytosis often coincides with ascites and the cytoreduction decreases platelet count. There is a positive correlation between platelet count and tumour grading. Thrombocytosis was more frequently found in high grade tumours. There is also a positive correlation between platelet count and tumour stage according the International Federation of Gynaecology and Obstetrics (FIGO). Thrombocytosis was more frequently found in stage III and IV cancers. Patients with co-occurring thrombocytosis were found to have shorter survival periods and shorter time free from disease.
Conclusion The present study suggested that the platelet count should be included in the panel of prognostic factors for patients with ovarian tumours
Disclosure Nothing to disclose
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.